Affiliation:
1. Department for Prevention and Care of Diabetes, Department of Medicine III, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany
2. Paul Langerhans Institute Dresden, Faculty of Medicine, Technische Universität Dresden, 01307 Dresden, Germany
Abstract
(1) Background: This study aimed at providing preliminary evidence for mebix, an app-based treatment program for patients with diabetes mellitus type II. The main target was to show a positive healthcare impact as defined by improved blood glucose control, i.e., reduced HbA1c values. (2) Methods: For this, a 3-month, prospective, open-label trial with an intraindividual control group was conducted. Participants received the mebix intervention for 3 months. HbA1c values were observed every 3 months: retrospectively, at baseline, and 3 months after the start of using the app. Additionally, weight and patients’ reported outcomes (well-being, diabetes-related distress, and self-management) were assessed. Data generated within the app were summarized and analyzed (steps, physical activity, fulfilled tasks, and food logs). (3) Results: After the usage of mebix for 3 months, participants significantly reduced their HbA1c levels (−1.0 ± 0.8%). Moreover, improvements in weight, well-being, and self-management as well as a reduction in diabetes-related distress were observed. App-generated data mainly supported the other main finding, that higher baseline HbA1c values lead to higher reductions. Overall, the study provided preliminary evidence that mebix can help patients improve metabolic and psychological health outcomes.
Reference29 articles.
1. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045;Sun;Diabetes Res. Clin. Pract.,2022
2. International Diabetes Federation (IDF) (2021). IDF Diabetes Atlas 2021, International Diabetes Federation (IDF). [10th ed.].
3. Prevalence, incidence and mortality of diabetes mellitus in adults in Germany—A review in the framework of the Diabetes Surveillanc;Heidemann;J. Health Monit.,2017
4. Prävalenz und Inzidenz des dokumentierten Diabetes mellitus—Referenzauswertung für die Diabetes-Surveillance auf Basis von Daten aller gesetzlich Krankenversicherten;Schmidt;Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz,2020
5. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD);Cosentino;Revista Española Cardiología Engl. Ed.,2020